See more : Ningbo Water Meter (Group) Co., LTD. (603700.SS) Income Statement Analysis – Financial Results
Complete financial analysis of MiMedx Group, Inc. (MDXG) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MiMedx Group, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- SHIFT Inc. (3697.T) Income Statement Analysis – Financial Results
- Bellicum Pharmaceuticals, Inc. (BLCM) Income Statement Analysis – Financial Results
- Vincent Medical Holdings Limited (1612.HK) Income Statement Analysis – Financial Results
- Trine II Acquisition Corp. (TRAQ) Income Statement Analysis – Financial Results
- China Health Industries Holdings, Inc. (CHHE) Income Statement Analysis – Financial Results
MiMedx Group, Inc. (MDXG)
About MiMedx Group, Inc.
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a semi-permeable protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications; and AMNIOBURN a semi-permeable protective barrier allograft used in the treatment of partial-thickness and full-thickness burns, as well as lead product includes mdHACM, a micronized form of AMNIOFIX, supplied in powder form. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. is headquartered in Marietta, Georgia.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 321.48M | 267.84M | 258.62M | 248.23M | 299.26M | 359.11M | 321.14M | 245.02M | 187.30M | 118.22M | 59.18M | 27.05M | 7.76M | 788.87K | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 54.63M | 48.32M | 43.28M | 39.33M | 43.08M | 36.39M | 35.22M | 32.41M | 20.20M | 12.67M | 9.33M | 5.19M | 3.15M | 1.72M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 266.84M | 219.53M | 215.33M | 208.90M | 256.17M | 322.73M | 285.92M | 212.61M | 167.09M | 105.56M | 49.85M | 21.87M | 4.61M | -931.19K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 83.01% | 81.96% | 83.26% | 84.16% | 85.60% | 89.87% | 89.03% | 86.77% | 89.21% | 89.29% | 84.24% | 80.82% | 59.35% | -118.04% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 12.67M | 22.83M | 17.34M | 11.72M | 11.14M | 15.77M | 17.90M | 12.04M | 8.41M | 7.05M | 4.84M | 2.88M | 2.60M | 2.75M | 4.02M | 2.01M | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.96M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 211.12M | 208.79M | 198.36M | 181.02M | 198.21M | 258.53M | 220.12M | 180.00M | 133.38M | 90.48M | 46.23M | 20.97M | 11.76M | 6.85M | 7.96M | 8.66M | 36.81K | 16.15K |
| Other Expenses | 5.94M | 12.88M | 4.61M | 60.54M | 67.54M | 527.00K | -87.00K | 2.13M | 933.00K | 928.00K | 1.05M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 229.73M | 244.50M | 220.31M | 253.28M | 276.89M | 326.65M | 239.70M | 194.16M | 142.73M | 98.46M | 52.12M | 23.86M | 14.37M | 9.60M | 11.98M | 10.67M | 36.81K | 16.15K |
| Cost & Expenses | 284.36M | 292.81M | 263.60M | 292.61M | 319.97M | 363.04M | 274.92M | 226.57M | 162.93M | 111.12M | 61.45M | 29.04M | 17.52M | 11.32M | 11.98M | 10.67M | 36.81K | 16.15K |
| Interest Income | 0.00 | 5.02M | 4.98M | 7.94M | 4.71M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 59.55K | 519.71K | 0.00 | 0.00 |
| Interest Expense | 6.46M | 5.02M | 4.98M | 7.94M | 4.71M | 0.00 | 0.00 | 339.00K | 86.00K | 48.00K | 1.37M | 2.31M | 432.97K | 599.65K | 0.00 | 0.00 | 2.05K | 590.00 |
| Depreciation & Amortization | 3.43M | 4.05M | 6.17M | 7.84M | 8.53M | 6.92M | 5.77M | 5.46M | 2.73M | 2.13M | 1.69M | 1.85M | 1.78M | 1.11M | 1.09M | 500.26K | 0.00 | 0.00 |
| EBITDA | 40.52M | -10.69M | -1.89M | -45.76M | -12.35M | 2.99M | 53.04M | 23.91M | 27.10M | 9.23M | -947.35K | -3.51M | -7.98M | -9.71M | -10.89M | -10.83M | -36.81K | -16.15K |
| EBITDA Ratio | 12.60% | -7.81% | 0.07% | -15.11% | -4.24% | 0.83% | 16.51% | 9.76% | 14.47% | 7.80% | -0.98% | -7.36% | -102.81% | -1,230.60% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | 37.12M | -24.97M | -5.01M | -44.37M | -20.71M | -3.92M | 46.22M | 18.45M | 24.36M | 7.10M | -2.64M | -5.36M | -9.76M | -10.53M | -11.98M | -17.85M | -36.81K | -16.15K |
| Operating Income Ratio | 11.55% | -9.32% | -1.94% | -17.87% | -6.92% | -1.09% | 14.39% | 7.53% | 13.01% | 6.01% | -4.46% | -19.80% | -125.78% | -1,335.15% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -6.48M | -5.02M | -2.99M | -16.15M | -4.43M | 527.00K | -1.14M | -339.00K | -86.00K | -48.00K | -1.37M | -2.31M | -432.97K | -887.10K | 59.55K | -5.39M | -2.05K | -634.63K |
| Income Before Tax | 30.63M | -29.99M | -10.04M | -61.54M | -25.59M | -3.40M | 45.09M | 18.11M | 24.28M | 7.05M | -4.01M | -7.66M | -10.19M | -11.42M | -11.92M | -17.37M | -38.86K | -16.74K |
| Income Before Tax Ratio | 9.53% | -11.20% | -3.88% | -24.79% | -8.55% | -0.95% | 14.04% | 7.39% | 12.96% | 5.96% | -6.78% | -28.32% | -131.36% | -1,447.60% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -36.81M | 206.00K | 247.00K | -12.26M | -5.00K | 26.58M | -19.64M | 6.13M | -5.17M | 832.00K | 99.61K | 2.31M | 432.97K | 887.10K | -59.55K | -477.93K | 0.00 | 0.00 |
| Net Income | 67.44M | -30.20M | -10.29M | -49.28M | -25.58M | -29.98M | 64.73M | 11.97M | 29.45M | 6.22M | -4.11M | -7.66M | -10.19M | -11.42M | -11.92M | -17.37M | -38.86K | -16.74K |
| Net Income Ratio | 20.98% | -11.27% | -3.98% | -19.85% | -8.55% | -8.35% | 20.16% | 4.89% | 15.72% | 5.26% | -6.95% | -28.32% | -131.36% | -1,447.60% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 0.48 | -0.27 | -0.09 | -0.46 | -0.24 | -0.28 | 0.61 | 0.00 | 0.28 | 0.06 | -0.04 | -0.09 | -0.14 | -0.19 | -0.32 | -3.00 | -0.01 | 0.00 |
| EPS Diluted | 0.38 | -0.27 | -0.09 | -0.46 | -0.24 | -0.28 | 0.56 | 0.00 | 0.26 | 0.05 | -0.04 | -0.09 | -0.14 | -0.19 | -0.32 | -3.00 | -0.01 | 0.00 |
| Weighted Avg Shares Out | 116.50M | 112.91M | 110.35M | 108.26M | 106.95M | 105.60M | 106.12M | 105.93M | 105.93M | 105.79M | 96.29M | 81.65M | 72.45M | 59.14M | 37.74M | 5.79M | 7.40M | 5.68M |
| Weighted Avg Shares Out (Dil) | 145.96M | 112.91M | 110.35M | 108.26M | 106.95M | 105.60M | 116.11M | 112.65M | 113.63M | 113.30M | 96.29M | 81.65M | 72.45M | 59.14M | 37.74M | 5.79M | 7.40M | 5.68M |
Recent Price Trend in MiMedx (MDXG) is Your Friend, Here's Why
Recent Price Trend in MiMedx (MDXG) is Your Friend, Here's Why
How Much Upside is Left in MiMedx (MDXG)? Wall Street Analysts Think 37.12%
MiMedx (MDXG) Is a Great Choice for 'Trend' Investors, Here's Why
MIMEDX's Advocacy to Rein in Runaway Medicare Spend for Skin Substitutes Has Yielded Significant Results with Planned Implementation of LCDs
Can MiMedx (MDXG) Climb 77.92% to Reach the Level Wall Street Analysts Expect?
MiMedx Group, Inc. (MDXG) Q3 2024 Earnings Call Transcript
MiMedx (MDXG) Q3 Earnings and Revenues Surpass Estimates
MIMEDX Announces Third Quarter 2024 Operating and Financial Results
MIMEDX to Host Third Quarter 2024 Operating and Financial Results Conference Call on October 30
Source: https://incomestatements.info
Category: Stock Reports